|Bid||23.68 x 1000|
|Ask||23.72 x 800|
|Day's Range||23.58 - 24.03|
|52 Week Range||17.56 - 32.00|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 28, 2022 - Apr 01, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.00|
LATHAM, N.Y., August 03, 2022--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference at 2:00 p.m. ET on Wednesday, August 10, 2022.
Earlier this month, AngioDynamics shared its financial results for the fourth quarter ended May 31. The Latham, New York-based medical device company topped both the analyst consensus for net sales and non-GAAP (adjusted) diluted earnings per share (EPS) in the quarter. AngioDynamics reported $87 million in net sales during the fourth quarter, which is equivalent to a 13.2% growth rate over the year-ago period.
"If we don't take risks like this," the CEO said, "we are not going to change the company."